drugset / Trial / NCT06822426

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

NCT06822426

Phase 3 Recruiting 200 enrolled CorMedix
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

Timeline

Start
2025-05-14
Primary completion
2028-01
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Heparin Other / unclassified
Subject taurolidine Small molecule

Indications

No indication recorded.